Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon R. Bhatnagar B, et al. Among authors: klisovic rb. Leuk Lymphoma. 2023 Dec;64(13):2091-2100. doi: 10.1080/10428194.2023.2253480. Epub 2023 Sep 4. Leuk Lymphoma. 2023. PMID: 37665178 Clinical Trial.
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Walker AR, et al. Leuk Lymphoma. 2013 Sep;54(9):1996-2002. doi: 10.3109/10428194.2012.760733. Epub 2013 Jan 24. Leuk Lymphoma. 2013. PMID: 23256542 Free PMC article. Clinical Trial.
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci G. Walker AR, et al. Leuk Lymphoma. 2016 Sep;57(9):2100-8. doi: 10.3109/10428194.2015.1135435. Epub 2016 Jan 19. Leuk Lymphoma. 2016. PMID: 26784138 Free PMC article.
Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon R. Bhatnagar B, et al. Among authors: klisovic rb. Leuk Lymphoma. 2020 Feb;61(2):387-396. doi: 10.1080/10428194.2019.1665664. Epub 2019 Sep 23. Leuk Lymphoma. 2020. PMID: 31545113 Free PMC article. Clinical Trial.
Phase I study of AR-42 and decitabine in acute myeloid leukemia.
Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR. Liva SG, et al. Leuk Lymphoma. 2020 Jun;61(6):1484-1492. doi: 10.1080/10428194.2020.1719095. Epub 2020 Feb 8. Leuk Lymphoma. 2020. PMID: 32037935 Free PMC article. Clinical Trial.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims AS. Saygin C, et al. Among authors: klisovic rb. Am J Hematol. 2020 Dec;95(12):1457-1465. doi: 10.1002/ajh.25958. Epub 2020 Sep 19. Am J Hematol. 2020. PMID: 32777116 Free PMC article. Clinical Trial.
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. Blum W, et al. Among authors: klisovic rb. J Clin Oncol. 2010 Nov 20;28(33):4919-25. doi: 10.1200/JCO.2010.30.3339. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956622 Free PMC article. Clinical Trial.
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Ranganathan P, et al. Blood. 2012 Aug 30;120(9):1765-73. doi: 10.1182/blood-2012-04-423160. Epub 2012 Jun 7. Blood. 2012. PMID: 22677130 Free PMC article.
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Mims A, et al. Among authors: klisovic rb. Leukemia. 2013 Apr;27(4):871-8. doi: 10.1038/leu.2012.342. Epub 2012 Nov 26. Leukemia. 2013. PMID: 23178755 Free PMC article.
72 results